Brief: GENFIT Says Data Shows Greater Efficacy Of Its Hepatitis Detection Test In Older Patients

Genfit SA

11/08/2023 06:17

Aug 11 (Reuters) - Genfit SA  GNFT.PA :
    * ANNOUNCED ON THURSDAY PUBLICATION OF NEW DATA ON THE
CLINICAL
PERFORMANCE OF NIS2+ IN OLDER PATIENTS, FOR THE DETECTION OF
AT-RISK NONALCOHOLIC STEATOHEPATITIS (NASH) IN HEPATOLOGY
COMMUNICATIONS
    * CLINICAL PERFORMANCE OF NIS2+ WAS SUPERIOR TO OTHER TESTS
FOR
THE DIAGNOSIS OF AT-RISK NASH IN PATIENTS ≥65 YEARS OF AGE,
GREATLY ASSISTING WITH CMS REIMBURSEMENT EFFORTS
    * THESE DATA SUPPORT THE CLINICAL VALUE OF THIS BLOOD-BASED
TEST
FOR THE DIAGNOSIS OF AT-RISK NASH IN OLDER ADULTS
    * DATA IS THE FIRST TO SHOW AND COMPARE THE CLINICAL
PERFORMANCE
OF NIS4 AND ITS RECENTLY DEVELOPED AND IMPROVED UPGRADE NIS2+ IN
A POPULATION OF OLDER ADULTS

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNX5BytRm
 Further company coverage:  GNFT.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))